Suven Pharma Hits All-Time High of Rs 1,245 After US FDA Closes Inspection

Sep 9, 2024, 04:45 AM

Suven Pharma's Hyderabad-based manufacturing facility, operated by its subsidiary Casper Pharma, received an Establishment Inspection Report (EIR) from the US FDA. The inspection, conducted between July 8-12, 2024, was categorized as Voluntary Action Indicated (VAI) and has been deemed closed. Following this disclosure, Suven Pharma's share price surged by up to 3.67%, reaching an all-time high of Rs 1,245 per share on the BSE.